Tagworks Pharmaceuticals has received CTA approval for the Phase 0/1 CleavHER trial of TGW211, a first-in-class HER2-directed radioimmunoconjugate developed with its Click-to-Release platform. Sponsored by Radboud University Medical Center, the study will evaluate safety, pharmacokinetics, and dosimetry in HER2-positive solid tumors, with first patient enrollment expected by the end of …

Tagworks Pharmaceuticals announces progress in its Phase 1 clinical trial of TGW101, a first-in-class antibody-drug conjugate (ADC) targeting TAG-72 in patients with advanced solid tumors. Following favorable safety reviews, the study has moved to the third dose level. Preliminary safety, pharmacokinetics, and early efficacy data are expected in early to …

Tagworks initiates Phase 1 trial for TGW101, a first-in-class Click-to-Release ADC targeting TAG-72, and appoints Dr. Keith Orford as Chief Medical Officer.

Biotech industry veteran to lead Tagworks as the company prepares to bring its novel platform and lead antibody-drug conjugate (ADC) program for solid tumors into the clinic in 2025

We are excited to announce a recent addition to our rapidly expanding team: Krisztina Nemenyi has joined as our Vice President Regulatory Affairs.

We are pleased to announce the appointment of Bianca Matthee as our VP of Research Operations.

We are pleased to announce the recent appointments of Maria V. Cincotta as our VP of Clinical Operations & Program Management and Tu-Anh T. Bui as our VP of CMC & Technical Operations.

Financing round led by Ysios Capital and Gilde Healthcare with participation from Novartis Venture Fund, New Enterprise Associates, and Lightstone Ventures Unique Click-to-Release platform enables on-target activation of antibody-drug conjugates (ADCs) and immunomodulators, as well as off-target deactivation of radiopharmaceuticals Proceeds will be used to advance the lead program, a …

Tagworks announces the completion of an investment round led by Meneldor (The Netherlands), Oost NL (The Netherlands), and a syndicate of high net-worth private investors. The proceeds of the financing will be used for the clinical development of Tagworks' lead program.    

A key patent that encompasses the therapeutic application scope of the Click-to-Release platform has been granted in the US (US 10,967,069 B2), further strengthening Tagworks’ IP portfolio. The patent titled “BIO-ORTHOGONAL DRUG ACTIVATION”, covers the invention of the pyridazine elimination reaction that underlies the Click-to-Release approach. The patent protects a …